Gleevec Sales Gains May Come From Increased Dosing Compliance
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis is hoping to boost sales of its oncologic Gleevec (imatinib) by increasing patient compliance with the daily dosing regimen